Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Cash Flow (2016 - 2026)

Insight Molecular Diagnostics' Net Cash Flow history spans 6 years, with the latest figure at -$7.3 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 237.91% to -$7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 450.13% increase, with the full-year FY2025 number at $2.7 million, up 450.13% from a year prior.
  • Net Cash Flow hit -$7.3 million in Q4 2025 for Insight Molecular Diagnostics, down from -$5.7 million in the prior quarter.
  • Over the last five years, Net Cash Flow for IMDX hit a ceiling of $51.8 million in Q1 2021 and a floor of -$15.2 million in Q1 2022.
  • Historically, Net Cash Flow has averaged $211000.0 across 5 years, with a median of -$5.0 million in 2023.
  • The widest YoY moves for Net Cash Flow: up 1041.85% in 2021, down 5764.38% in 2021.
  • Tracing IMDX's Net Cash Flow over 5 years: stood at -$7.7 million in 2021, then crashed by 36.39% to -$10.5 million in 2022, then skyrocketed by 58.76% to -$4.4 million in 2023, then skyrocketed by 221.26% to $5.3 million in 2024, then crashed by 237.91% to -$7.3 million in 2025.
  • Business Quant data shows Net Cash Flow for IMDX at -$7.3 million in Q4 2025, -$5.7 million in Q3 2025, and -$6.7 million in Q2 2025.